ClinicalTrials.gg
WithdrawnNCT06547294Updated Oct 22, 2026

Does a Novel Needle Over Catheter Device Improve First Pass Success and Decrease Complications

An interventional study of Osprey IV and Historical Controls in Vascular Access Device Complications and Catheterization, Peripheral, sponsored by Community Medical Center, Toms River, NJ. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Community Medical Center, Toms River, NJ · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Device manufacturer withdrew support
Updated Oct 22, 2026Now WithdrawnEnrollment updatedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Emergency Department Patients who were to get intravenous (IV) access through routine medical care will receive it through trademarked catheter via convenience sample. Patient and clinician experience, including adverse events, will be recorded. A standardized data entry sheet will be collected at time of enrollment, and then daily thereafter while the subject has the IV. The data collected will remain anonymous.

Read the detailed description

Identification of Subjects:

The emergency department is a designated participating unit providing subjects with medical care that are anticipated to be placed in the observation unit or admitted to an inpatient unit. Subjects who meet inclusion criteria will be consented to be included in the study.

Assignment of Subject Identification Number:

A unique identification number will be given to study subjects. Subject numbers will be assigned in sequential order. The subject number will consist of 6 characters. The first three characters will designate the manufacturer-specific protocol number (SVI). The last three characters will designate the subject by number in sequential order.

Informed Consent:

The nurse trained in placing this device will first consent the patient with written forms provided. All protocol nurses trained in this device will also have completed CITI training courses per our institutional guidelines.

Treatment Assignment:

Within this single arm study, subjects will be assigned to the study in a single treatment group. All patients in the convenience sample who would have received a standard stocked intravenous catheter will instead receive an Osprey catheter provided by the manufacturer. They will be compared against historical controls. Historical controls will be collected from a review of relevant literature, which has been determined to be stable across time and region.

Data Collection Method A Case Report Form (CRF) will be utilized to collect insertion related study data. The CRF will not include any patient identifying information such as name or medical identification number. The subject's demographic (age, race, and gender); baseline information (comorbidities); type of medications/fluids delivered will be documented from already captured Epic documentation.

A second Case Report Form (CRF) will be utilized to collect device performance study data. The CRF will not include any patient identifying information such as name or medical identification number. Device condition (ability to flush and obtain a blood return), Site condition (presence of redness, edema, drainage), patient response (level of pain) and dwell time will be extracted from Epic as this is the current standard practice to do so.

Active patients in the study will be maintained in a file on a secure drive that study personnel have to refer to to follow up active patients. Once active patients are no longer being followed daily, their name will be removed from that file. CRF forms will be filled out by hand and secured in a locked box. The data from both CRFs will be transcribed into a digital worksheet i.e. Microsoft Excel, which will be stored on a secured network drive maintained by the hospital.

Study Procedure Subjects will be admitted into the study according to the aforementioned criteria.

Hospital protocols will be followed for placement of the PIV. The site will be marked with date, time and initials of inserter. During and immediately after the IV placement procedure, the CRF will be initiated by staff associated with this study. If unsuccessful with first attempt at PIV placement, an attempt at another site with the same technique and device will be performed. This will be repeated according to facility policy and procedure until a successful PIV is in place or the physician decides to use an alternative therapy that no longer requires peripheral access. All catheters will be stabilized using the same form of stabilization device for uniformity in securement procedure throughout the duration of the study.

Daily assessments will occur per facility policy and procedure. An assessment will include; any level of pain and/or tenderness; presence of erythema; edema; induration; leakage of fluid or purulent drainage from the puncture site; catheter dysfunction (eg, resistance when flushing, absence of a blood return. Daily assessment will continue until the device is removed, completion of therapy or discharge. Once all the required data is collected, all de-identified data will be entered as a "data set" into the post procedure CRF for management/analysis. The final paper CRF will be placed in a study folder and maintained for record keeping and data analysis.

02

Conditions studied

  • Vascular Access Device Complications
  • Catheterization, Peripheral
03

In context

Lead sponsor

Community Medical Center, Toms River, NJ is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria i. Any gender, 18 years of age or older ii. Acceptable candidate for an elective PIV as determined by physician. iii. Anticipated admission to inpatient unit.

Exclusion Criteria

  1. Any gender, \< 18 years old.
  2. Requirement for emergent IV placement (patient's condition would be compromised if there is a delay in IV placement);
  3. Previous venous grafts or surgery at the target vessel access site;
  4. Currently involved in other clinical trials (unless permission is granted by other study Pl)
  5. Subjects who are pregnant, planning to become pregnant within 3 months of the procedure, or lactating
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Osprey IV

    Subjects enrolled will receive the study device as part of their routine medical care.

    Device: Osprey IV · Other: Historical Controls

Interventions

  • DeviceOsprey IV

    Utilization of novel needle over catheter commercial insertion device

  • OtherHistorical Controls

    Outcome rates from catheter over needle devices (traditional manner of inserting peripheral IV)

06

What researchers measure

Primary outcomes

  1. Number of Attempts

    The number of attempts that operator needs to access vein and secure device for proper bidirectional flow

    Time frame: 10 minutes

Secondary outcomes

  1. Blood culture contamination rates

    Proportion of blood culture specimens (when drawn) that are reported with contaminants

    Time frame: 1 week

  2. Flushing characteristic

    whether operator finds flow into patient to be impeded or unimpeded

    Time frame: 10 minutes

  3. Patient discomfort

    Patient's self assessment of level of pain experienced by insertion

    Time frame: 10 minutes

  4. Time to removal

    Total days device remained in place

    Time frame: 1 week

  5. Removal reason

    If removed for device failure vs cessation of therapy

    Time frame: 1 week

  6. Edema

    Presence of edema

    Time frame: 1 week

  7. Redness

    Presence of redness

    Time frame: 1 week

  8. Drainage

    Presence of drainage

    Time frame: 1 week

  9. Site Pain

    Presence of site pain

    Time frame: 1 week

07

Study locations

1 site
  • Robert Wood Johnson Barnabas Health Community Medical Center
    Toms River, New Jersey 08755, United States
08

References and documents

Individual participant data

Plan to share: No

09

Updates

1 registry update since Sep 25, 2026
Status
Suspended→Withdrawn Device manufacturer withdrew support
changed Oct 22, 2026
Enrollment
200 (estimated)→0 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Suspended→Withdrawn
    Why stopped Device manufacturer withdrew support
    Enrollment 200 (estimated)→0 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06547294
Lead sponsor
Community Medical Center, Toms River, NJ
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Feb 2025 (estimated)
Primary completion
Apr 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Oct 22, 2026

Study contacts

Gerado Chiricolo, MD
principal investigator · Robert Wood Johnson Barnabas Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion